Skip to main content
SpringerLink
Log in

Antithrombotika und Antihämorrhagika

  • Chapter
Arzneiverordnungs-Report 2015

Zusammenfassung

In der Gruppe der Antithrombotika sind die Gesamtverordnungen der Thrombozytenaggregationshemmer im Jahr 2014 um 3% und der Antikoagulantien um 12% angestiegen. Wie bereits im Vorjahr haben die Verordnungen der Vitamin-K-Antagonisten in 2014 weiter abgenommen, während die Verordnungen der Thrombin- und Faktor Xa-Antagonisten um 69% zugenommen haben. Apixaban, Dabigatran und Rivaroxaban erreichten 29% der Verordnungen der oralen Antikoagulantien. Bei den Thrombozytenaggregationshemmern stieg der Verordnungsanteil von Prasugrel und Ticagrelor auf 15% der ADP-Rezeptorantagonisten. Bei den Antihämorrhagika sind die Faktor-VIII-Präparate die umsatzstärkste Gruppe. Die Kosten der Antithrombotika sind 2014 auf 1,4 Mrd. € (+22%) gestiegen, was vor allem durch die neuen direkten oralen Antikoagulantien bedingt ist.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI, Investigators A (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369: 799–808

    Article  CAS  PubMed  Google Scholar 

  • Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI, Investigators P-E (2013) Apixaban for extended treatment of venous thromboembolism. N Engl J Med 368: 699–708

    Article  CAS  PubMed  Google Scholar 

  • Algra A, de Schryver EL, van Gijn J, Kappelle LJ, Koudstaal PJ (2001): Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev 2001 (4): CD 001342 Antithrombotic Trialists'

    Google Scholar 

  • Collaboration (2002): Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Brit Med J 324: 71–86

    Article  PubMed Central  Google Scholar 

  • Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators (2006): Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354: 1706–1717

    Article  CAS  PubMed  Google Scholar 

  • Bonello L, Laine M, Kipson N, Mancini J, Helal O, Fromonot J, Gariboldi V, Condo J, Thuny F, Frere C, Camoin-Jau L, Paganelli F, Dignat-George F, Guieu R (2014): Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol 63: 872–877

    Article  CAS  PubMed  Google Scholar 

  • Bowry ADK, Brookhart MA, Choudhry NK (2008): Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared with antiplatelet monotherapy for the prevention of vascular events. Am J Cardiol 101: 960–966

    Article  CAS  PubMed  Google Scholar 

  • Bundesministerium für Gesundheit (2014): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage III - Übersicht der Verordnungseinschränkungen und -ausschlüsse Dipyridamol in Kombination mit Acetylsalicylsäure vom 16. Mai 2013, veröffentlicht am Dienstag, 25. Februar 2014 BAnz AT 25.02.2014 B–2

    Google Scholar 

  • Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, ESC Committee for Practice Guidelines-CPG, Document Reviewers (2012): 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation-developed with the special con- tribution of the European Heart Rhythm Association. Europace 14: 1385–1413

    Article  PubMed  Google Scholar 

  • CAPRIE Steering Committee (1996): A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329–1339

    Article  Google Scholar 

  • Cattaneo M, Schulz R, Nylander S (2014): Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol 63: 2503–2509

    Article  CAS  PubMed  Google Scholar 

  • Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, Hui AJ, Wu JC, Leung WK, Lee VW, Lee KK, Lee YT, Lau JY, To KF, Chan HL, Chung SC, Sung JJ (2005): Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352: 238–244

    Article  CAS  PubMed  Google Scholar 

  • Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G (2009): Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373: 309–317

    Article  CAS  PubMed  Google Scholar 

  • Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA,

    Google Scholar 

  • Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators (2009): Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 361: 1139–1151

    Google Scholar 

  • Cuker A, Siegal DM, Crowther MA, Garcia DA (2014) Laboratory measurement of the anti- coagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 64: 1128113–9

    Article  Google Scholar 

  • De Schryver ELLM, Algra A, van Gijn MD (2003): Cochrane Review: Dipyridamole for preventing major vascular events in patients with vascular disease. Stroke 34: 2072–2080

    Article  CAS  PubMed  Google Scholar 

  • Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ; MATCH investigators (2004): Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk pa- tients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364: 331–337

    Article  CAS  PubMed  Google Scholar 

  • Eikelboom JW, Anand SS, Maimberg K, Weitz JI, Ginsberg JS, Yusuf S (2000): Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 355: 1936–1942

    Article  CAS  PubMed  Google Scholar 

  • Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S (2003): Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in pa- tients at high risk for cardiovascular events. Circulation 105: 1650–1655

    Article  Google Scholar 

  • Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F; RE-ALIGN Investigators (2013): Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369: 1206–1214

    Article  CAS  PubMed  Google Scholar 

  • EINSTEIN-Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363: 2499–2510

    Google Scholar 

  • EINSTEIN-PE Investigators, Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366: 1287–1297

    Google Scholar 

  • Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W, RECORD1 Study Group (2008): Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 358: 2765–2775

    Article  Google Scholar 

  • European Medicines Agency (2011): Updates on safety of PRADAXA; Pressemitteilung vom 18. Nov. 2011.Internet : www.ema.europa.eu/docs/en_GB/document_library/Press_release/>2011/11/WC500117818.pdf

  • Gemeinsamer Bundesausschuss (2012): Bekanntmachung des Beschlusses des Gemeinsamen Bundesausschusses. Ticagrelor. Bundesanzeiger 11: S254 Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators (2011): Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365: 981–992

    Google Scholar 

  • Grau E, Tenias JM, Real E, Medrano J, Ferrer R, Pastor E, Selfa S (2001): Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism. Am J Hematol 67: 10–14

    Article  CAS  PubMed  Google Scholar 

  • Greinacher A, Thiele T, Selleng K (2015) Reversal of anticoagulants: an overview of current developments. Thromb Haemost 113: 931–942

    Article  PubMed  Google Scholar 

  • Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, O'Gara P, Whitlow P; American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions; American College of Surgeons; American Dental Association; American College of Physicians (2007): Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 115: 813–818

    Article  PubMed  Google Scholar 

  • Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ (2001): Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88: 230–235

    Article  CAS  PubMed  Google Scholar 

  • Harper P, Young L, Merriman E (2012): Bleeding risk with dabigatran in the frail elderly. N Engl J Med 366: 864–867

    Article  CAS  PubMed  Google Scholar 

  • Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS (2009): Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301: 937–944

    Article  CAS  PubMed  Google Scholar 

  • Hoots WK, Nugent DJ (2006): Evidence for the benefits of prophylaxis in the management of hemophilia A. Thromb Haemost 96: 433–440

    CAS  PubMed  Google Scholar 

  • January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; ACC/AHA Task Force Members (2014): 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130: 2071–2104

    Article  Google Scholar 

  • Jensen CF, Christensen TD, Maegaard M, Hasenkam JM (2009): Quality of oral anticoagulant therapy in patients who perform self management: warfarin versus phenprocoumon. J Thromb Thrombolysis 28: 276–281

    Article  PubMed  Google Scholar 

  • Jneid H, Bhatt DL, Corti R, Badimon JJ, Fuster V, Francis GS (2003): Aspirin and clopidogrel in acute coronary syndromes. Therapeutic insights from the CURE study. Arch Intern Med 163: 1145–1153

    Article  CAS  PubMed  Google Scholar 

  • Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, Henry DA, Kopp A, Mamdani MM., Szmitko PE, Austin PC, Tu JV, Henry DA, Kopp A, Mamdani MM. (2009): A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180: 713–718

    Article  PubMed Central  PubMed  Google Scholar 

  • Keng TB (2001): Heparin-induced thrombocytopenia and thrombosis syndrome: in vivo cross-re- activity with danaparoid and successful treatment with r-Hirudin. Br J Haematol 114: 394–396

    Article  CAS  PubMed  Google Scholar 

  • Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH (1996): Treatment of venous thrombosis with

    Google Scholar 

  • intravenous unfractionated heparin administered in the hospital as compared with subcu- taneous low-molecular-weight heparin administered at home. N Engl J Med 334: 682–687

    Google Scholar 

  • Kwok CS, Loke YK (2010): Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 31: 810–823

    CAS  PubMed  Google Scholar 

  • Larsen TB, Rasmussen LH, Skj0th F, Due KM, Callreus T, Rosenzweig M, Lip GY (2013): Efficacy and safety of dabigatran etexilate and warfarin in „real-world" patients with atrial fibrilla- tion: a prospective nationwide cohort study. J Am Coll Cardiol 61: 2264–2273

    Google Scholar 

  • Leiria TL, Pellanda L, Miglioranza MH, Sant'anna RT, Becker LS, Magalhäes E, Lima GG (2010): Warfarin and phenprocoumon: Experience of an outpatient anticoagulation clinic. Arq Bras Cardiol. 94: 40–43

    Article  CAS  Google Scholar 

  • Lensing AWA, Prins MH, Davidson BL, Hirsh J (1995): Treatment of deep venous thrombosis with low-molecular-weight heparins: a meta-analysis. Arch Intern Med 155: 601–607

    Article  CAS  PubMed  Google Scholar 

  • Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M. (1996): A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334: 677–681

    Article  CAS  PubMed  Google Scholar 

  • Martel N, Lee J, Wells PS (2005): Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106: 2710–2715

    Article  CAS  PubMed  Google Scholar 

  • Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BL, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA; Clopidogrel in Unstable angina to prevent Recur- rent Events trial (CURE) Investigators. (2001): Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients underoing percutaneous coronary intervention: The PCI-CURE study. Lancet 358: 527–533

    Article  CAS  PubMed  Google Scholar 

  • Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ (2012): Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 110: 453–460

    Article  CAS  PubMed  Google Scholar 

  • Mismetti P, Laporte S, Darmon J-Y, Buchmüller A, Decousus H (2001): Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 88: 913–930

    Article  CAS  PubMed  Google Scholar 

  • National Institute for Care Exellence (2014): Atrial fibrillation: the management of atrial fibrillation. Issued: June 2014 last modified: August 2014. NICE clinical guideline 180. Internet: guidance.nice.org.uk/cg180

    Google Scholar 

  • Neubauer H, Krüger JC, Lask S, Endres HG, Pepinghege F, Engelhardt A, Bulut D, Mügge A (2009): Comparing the antiplatelet effect of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study. Clin Res Cardiol 98: 533–540

    Article  CAS  PubMed  Google Scholar 

  • Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, Han KH, Park SW, Yun SC, Lee SG, Rha SW, Seong IW, Jeong MH, Hur SH, Lee NH, Yoon J, Yang JY, Lee BK, Choi YJ, Chung WS, Lim DS, Cheong SS, Kim KS, Chae JK, Nah DY, Jeon DS, Seung KB, Jang JS, Park HS, Lee K (2010): Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 362: 1374–1382

    Article  CAS  PubMed  Google Scholar 

  • Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators (2011): Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 365: 883–891

    Article  CAS  PubMed  Google Scholar 

  • Romualdi E, Donadini MP, Ageno W (2011) Oral rivaroxaban after symptomatic venous throm- boembolism: the continued treatment study (EINSTEIN-extension study). Expert Rev Cardiovasc Ther 9: 841–844

    Article  CAS  PubMed  Google Scholar 

  • Salazar CA, del Aguila D, Cordova EG (2014): Direct thrombin inhibitors versus vitamin K anta- gonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev. 2014 Mar 27; 3: CD009893 Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C, Investigators R-CIT (2014) Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129: 764–772

    Google Scholar 

  • Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ, Group R-CS (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361: 2342–2352

    Article  CAS  PubMed  Google Scholar 

  • Silber S, Borggrefe M, Hasenfuß G et al (2010): Kommentare zu den Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zur Diagnostik und Therapie von Patienten mit ST-Stre- ckenhebungsinfarkt (STEMI). Kardiologie 4: 84–92

    Article  Google Scholar 

  • Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, Steg PG, Ferneres J, Danchin N, Becquemont L; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators (2009): Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360: 363–375

    Article  CAS  PubMed  Google Scholar 

  • Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding (2013): N Engl J Med 368: 1272–1274

    Article  CAS  PubMed  Google Scholar 

  • Stangier J, Rathgen K, Stahle H, Mazur D (2010): Influence of renal impairment on the pharma- cokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, paral- lel-group, single- centre study. Clin Pharmacokinet. 49: 259–268

    Article  CAS  PubMed  Google Scholar 

  • The ACTIVE Investigators (2009): Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 360: 2066–2078

    Article  Google Scholar 

  • The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001): Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. N Engl J Med 345: 494–502

    Article  Google Scholar 

  • The Warfarin Antiplatelet Vascular Evaluation Trial Investigators (2007): Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 357: 217–227

    Article  Google Scholar 

  • Van de Werf F, Bax J, Betriu A. Blomstrom-Lundqvist, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M; ESC Committee for Practice Guidelines (CPG) (2008): Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 29: 2909–2945

    Article  Google Scholar 

  • Van der Heijden JF, Hutten BA, Büller HR, Prins MH (2002): Vitamin K antagonists or low-molec- ular-weight heparin for the long term treatment of symptomatic venous thromboembo- lism (Cochrane Reviews). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software Walenga JM (2002): Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res 105: 401–405

    Article  Google Scholar 

  • Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO

    Google Scholar 

  • Investigators, Freij A, Thorsen M (2009): Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361: 1045–1057

    Google Scholar 

  • Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Wang C, Li H, Meng X, Cui L, Jia J, Dong Q, Xu A, Zeng J, Li Y, Wang Z, Xia H, Johnston SC; CHANCE Investigators (2013): Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 369: 11–19

    Article  CAS  PubMed  Google Scholar 

  • White RH, Ginsberg JS (2003): Low-molecular-weight heparins: are thy all the same? Br J Hematol 121: 12–20

    Article  CAS  Google Scholar 

  • Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators (2007): Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001–2015

    Google Scholar 

  • Zed PJ, Tisdale JE, Borzak S (1999): Low-molecular-weight heparins in the management of acute coronary syndromes. Arch Intern Med 159: 1849–1857

    Article  CAS  PubMed  Google Scholar 

Download references

Authors
  1. Lutz Hein
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

    Rights and permissions

    Reprints and permissions

    Copyright information

    © 2015 Springer-Verlag Berlin Heidelberg

    About this chapter

    Cite this chapter

    Hein, L. (2015). Antithrombotika und Antihämorrhagika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2015. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-47186-9_14

    Download citation

    • DOI: https://doi.org/10.1007/978-3-662-47186-9_14

    • Publisher Name: Springer, Berlin, Heidelberg

    • Print ISBN: 978-3-662-47185-2

    • Online ISBN: 978-3-662-47186-9

    • eBook Packages: Medicine (German Language)

    Publish with us

    Policies and ethics

    Search

    Navigation